Диссертация (1174209), страница 25
Текст из файла (страница 25)
et al.. Heterogeneity of multiplesclerosis lesions: Implications for the pathogenesis of demyelination./ Lucchinetti C,BrпїЅck W, Parisi J, Scheithauer B. et al..// Annals of Neurology. – 2000/ - N 47(6)– p.707-717;64.Bitsch A. Acute axonal injury in multiple sclerosis: Correlation with demyelinationand inflammation./ Bitsch A.// Brain. – 2000/ - N 123(6) – p.1174-1183;65.Kutzelnigg A. Cortical demyelination and diffuse white matter injury in multiplesclerosis./ Kutzelnigg A.// Brain. – 2005.
– N 128(11) – p.2705-2712;66.Leech S, Kirk J, Plumb J, McQuaid S. Persistent endothelial abnormalities andblood-brain barrier leak in primary and secondary progressive multiple sclerosis./Leech S, Kirk J, Plumb J, McQuaid S.// Neuropathol Appl Neurobiol. – 2007. – N33(1) – p. 86–98;67.Filippi M, Rocca M, Ciccarelli O. et al. MRI criteria for the diagnosis of multiplesclerosis: MAGNIMS consensus guidelines./ Filippi M, Rocca M, Ciccarelli O.
etal. // The Lancet Neurology. – 2016/ - N 15(3) – p.292-303;68.Montalban X, Sastre-Garriga J, Filippi M et al. Primary progressive multiplesclerosis diagnostic criteria: a reappraisal./ Montalban X, Sastre-Garriga J, Filippi Met al. // Multiple Sclerosis. – 2009. – N 15(12) – p.1459-1465;69.Polman C, Reingold S, Banwell B et al.
Diagnostic criteria for multiple sclerosis:2010 Revisions to the McDonald criteria./ Polman C, Reingold S, Banwell B et al.//Annals of Neurology. – 2011. – N - 69(2) – p.292-302.;16570.Kelly S, Kinsella K, Duggan M, Tubridy N. et al.. A proposed modification to theMcDonald 2010 criteria for the diagnosis of primary progressive multiple sclerosis./Kelly S, Kinsella K, Duggan M, Tubridy N. et al..// Multiple Sclerosis Journal. –2012.
– N 19(8) – p.1095-1100;71.Thompson AJ, Banwell BL, Barkhov F, et al. Diagnosis of multiple sclerosis:2017revisions of McDonald criteria./ Thompson AJ, Banwell BL, Barkhov F, et al.//Lancet Neurol. – 2017. – N 17 – p.162–173;72.Freedman M.S., Rush C.A. Severe, highly active or aggressive Multiple Sclerosis./Freedman M.S., Rush C.A.// Continuum (Minneap Minn). – 2016. – N 22(3) –p.761-784;73.Balo J. Encephalitis periaxialis concentrica./ Balo J.// Arch Neur Psych.
– 1928. – N19 – p. 242–64;74.Wallner-Blazek M, Rovira A, Fillipp M, et al. Atypical idiopathic inflammatorydemyelinating lesions: prognostic implications and relation to multiple sclerosis./Wallner-Blazek M, Rovira A, Fillipp M, et al.// J Neurol. – 2013. – N 260 - p 2016–22;75.Seewann A, Enzinger C, Filippi M, et al. and the MAGNIMS network. MRIcharacteristics of atypical idiopathic inflamatory demyelinating lesions of the brain:a review of reported findings./ Seewann A, Enzinger C, Filippi M, et al. and theMAGNIMS network.//J Neurol. – 2008. - N 255 – p.
1–10;76.Tabira T. Concentric sclerosis (Balo’s disease). In: Lisak RP, Truong DD, CarrollWM, Bhidayasiri R. (Editors). International neurology a clinical approach. Sussex:Blackwell Publishing, 2009 – 389p;77.Pineda A. Balo’s sclerosis in the Philippines: what has changed? Symposium 2.MRI experience: East and West./ Pineda A.//Mult Scler. - 2009. - N15 – p.132;78.Altintas A, Petek B, Isik N, et al.
Clinical and radiological characteristics oftumefactive demyelinating lesions: follow-up study./ Altintas A, Petek B, Isik N, etal. // Mult Scler. – 2012. - N 18 – p 1448–53;16679.Chaodong Wang, Zhang KN, Wu XM, et al. Balo’s disease showing benign clinicalcourse and co-existence with multiple sclerosis-like lesions in Chinese./ ChaodongWang, Zhang KN, Wu XM, et al.// Mult Scler. – 2008. - N 14 – p.
418–24;80.Hu W, Lucchinetti CF. The pathological spectrum of CNS inflammatorydemyelinating diseases./ Hu W, Lucchinetti CF.// Semin Immunopathol. – 2009. –N 31 – p. 439–53;81.Hardy T., Miller D. Baló's concentric sclerosis./ Hardy T., Miller D. // The LancetNeurology. – 2014. – N 13(7) – p.
740-746;82.Брюхов В.В., Куликова С.Н., Кротенкова И.А., Кротенкова М.В. и др.. МРТ вдиагностике рассеянного склероза./ Брюхов В.В., Куликова С.Н., КротенковаИ.А., Кротенкова М.В. и др..// Медицинская визуализация. – 2014. – N 2. – с.10-21;83.Воробьева А.А., Коновалов Р.Н., Кротенкова М.В., Переседова А.В. и др..Склероз Бало и Бало-подобные синдромы: диагностика и лечение./ ВоробьеваА.А., Коновалов Р.Н., Кротенкова М.В., Переседова А.В. и др..// Анналыклинической и экспериментальной неврологии. – 2015. – N 1. – с.
37-40;84.Markiewicz D, Adamczewska-Goncerzewicz Z, Dymecki J, Goncerzewicz A. Acase of primary form of progressive multifocal leukoencephalopathy with concentricdemyelination of Balo´ type./ Markiewicz D, Adamczewska-Goncerzewicz Z,Dymecki J, Goncerzewicz A// Neuropatol Pol. - 1977. - N 15 – p.491–500;85.Masuda H, Mori M, Katayama K, Kikkawa Y.
et al.. Anti-aquaporin-4 antibodyseronegative NMO spectrum disorder with Balo’s concentric lesions./ Masuda H,Mori M, Katayama K, Kikkawa Y. et al..// Intern Med. – 2013. – N 52 – p. 1517–21;86.Pohl D, Rostasy K, Krone B, Hanefeld F.. Balo´’s concentric sclerosis associatedwith primary human herpesvirus 6 infection./ Pohl D, Rostasy K, Krone B, HanefeldF.// J Neurol Neurosurg Psychiatry.
– 2005. - N 76 – p. 1723–1725;87.Graber JJ, Kister I, Geyer H, Khaund M. et al.. Neuromyelitis optica and concentricrings of Balo in the brainstem./ Graber JJ, Kister I, Geyer H, Khaund M. et al.//Arch Neurol. – 2009. - N 66 – p. 274–75;16788.Chitnis T, Hollmann TJ.. CADASIL mutation and Balo concentric sclerosis: a linkbetween demyelination and ischemia?/ Chitnis T, Hollmann TJ.// Neurology. –2012.
- N 78 – p. 221–23;89.http://www.medmerits.com/index.php/article/balo_concentric_sclerosis/2012;90.Hussein A Algahtani, Bader Shirah, Ali Alassiri. Tumefactive DemyelinatingLesions: A Comprehensive Review./ Hussein A Algahtani, Bader Shirah, AliAlassiri.// Multiple Sclerosis and Related Disorders. - 2017. – N 14 – p.72-79;91.Masdeu JC1, Quinto C, Olivera C, Tenner M.
et al.. Open-ring imaging sign: highlyspecific for atypical brain demyelination./ Masdeu JC1, Quinto C, Olivera C, TennerM. et al..// Neurology. – 2000. - N 54(7) – p. 1427-33;92.Guillain B, Alajouanine T. La forme aigue de la sclerose en plaques./ Guillain B,Alajouanine T.// Bul Acad Med. – 1928. – N 99 – p.366-76;93.Banerjee AK, Chopra JS, Kunar BR. Acute multiple sclerosis: report of a case withneuropathological and neurochemical studies./ Banerjee AK, Chopra JS, KunarBR.// Neurol India. – 1977. - N 25 – p.233 -7;94.Leary S, Miller D, Stevenson V, Brex P. et al..
Interferon В-1a in primaryprogressive MS: An exploratory, randomized, controlled trial./ Leary S, Miller D,Stevenson V, Brex P. et al..// Neurology. – 2003. – N 60(1) – p.44-51;95.Montalban X, Sastre-Garriga J, Tintore M et al. A single-center, randomized,double-blind, placebo-controlled study of interferon beta-1b on primary progressiveand transitional multiple sclerosis./ Montalban X, Sastre-Garriga J, Tintore M et al.//Multiple Sclerosis. – 2009. – N 15(10) – p.1195-1205;96.Wolinsky J, Narayana P, O'Connor P et al. Glatiramer acetate in primaryprogressive multiple sclerosis: Results of a multinational, multicenter, double-blind,placebo-controlled trial./ Wolinsky J, Narayana P, O'Connor P et al.// Annals ofNeurology. – 2007.
– N 61(1) – p.14-24;97.Lublin F, Miller D, Freedman M et al. Oral fingolimod in primary progressivemultiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebocontrolled trial./ Lublin F, Miller D, Freedman M et al.// The Lancet. – 2016. – N387(10023) – p.:1075-1084;16898.Szczucinski A and Losy J. Chemokines and chemokine receptors in multiplesclerosis. Potential targets for new therapies./ Szczucinski A and Losy J// ActaNeurol Scand. – 2007. - N 115 – p. 137–146;99.Hawker K, O'Connor P, Freedman M et al. Rituximab in patients with primaryprogressive multiple sclerosis: Results of a randomized double-blind placebocontrolled multicenter trial./ Hawker K, O'Connor P, Freedman M et al.// Annals ofNeurology. – 2009. – N 66(4) – p.460-471;100.
Susman E. News from the ECTRIMS Annual Meeting./ Susman E.// NeurologyToday. – 2015. – N 15(21) – p.10-11;101. Brown JW, Coles AJ, Jones JL. First use of alemtuzumab in Balo’s concentricsclerosis: a case report./ Brown JW, Coles AJ, Jones JL.// Mult Scler. – 2013. - N 19– p. 1673–75;102. Berghoff M, Schlamann MU, Maderwald S, et al. 7 Tesla MRI demonstratesvascular pathology in Balo’s concentric sclerosis./ Berghoff M, Schlamann MU,Maderwald S, et al.// Mult Scler. – 2013.
- N 19 – p. 120–22;103. Akkad, D.A., et al.. Sex specifically associated promoter polymorphism inmultiple sclerosis affects interleukin 4 expression levels./ Akkad, D.A., et al..//Genes Immun. - 2007. - N 8(8) - p. 703-6;104. Fishman, D., et al., The effect of novel polymorphisms in the interleukin-6 (IL-6)gene on IL-6 transcription and plasma IL-6 levels, and an association with systemiconset juvenile chronic arthritis./ Fishman, D., et al.// J Clin Invest. - 1998. – N102(7) - p.
1369-76;105. Liu, X.K., X. Lin, and S.L. Gaffen, Crucial role for nuclear factor of activated Tcells in T cell receptor-mediated regulation of human interleukin-17./ Liu, X.K., X.Lin, and S.L.// J Biol Chem. - 2004. - N 279(50) - p. 52762-71;106. Huang P, Dong L, Lu X et al. Genetic variants in antigen presentation-relatedgenes influence susceptibility to hepatitis C virus and viral clearance: a case controlstudy./ Huang P, Dong L, Lu X et al.// BMC infectious diseases. – 2014. - N14 –p.716;169107.
Leikfoss IS, Mero IL, Dahle MK et al. Multiple sclerosis-associatedsinglenucleotide polymorphisms in CLEC16A correlate with reduced SOCS1 andDEXI expression in the thymus./ Leikfoss IS, Mero IL, Dahle MK et al.// Genes andimmunity. – 2013. – N 14(1) – p.62-66;108. Zuvich, R.L., et al..
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
